Digistain® works biologically downstream using a proprietary method to measure markers at the protein level to deliver a robust and personalised risk score for cancer therapy guidance
Clinical Case Study - Identification of High Risk Patient
Clinical Case Study - Identification Low Risk Patient
Subscribe to leading news and insights
To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.